Prevalence of Omicron variant during the third wave of COVID-19 at a tertiary care hospital in Western Maharashtra

Singh, Sharanjit; Tandel, Kundan; Kalra, Dinesh; Babu, Bhagya; Thosani, Pratik; Anand, Kuldip Parkash

doi:10.1016/j.mjafi.2022.08.009

Cited by 1 publication

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BA.1 was 93.3% prevalent in India in January 2022 which was taken over by BA.2 between January and February 2022. 80 , 86 Hong Kong showed a similar predominance of the BA.2 subvariant between December 2021 and March 2022 50 ( Figure 4(d) ).…”

Section: Resultsmentioning

confidence: 79%

“…Overall, the Omicron variant predominated during the second time frame in India 90.65% (January-February), 80 , 86 Hong Kong 95.6% (December, 2021-March, 2022) 51 and Japan 99.5% (January, 2022) 82 but not in China or Russia where prevalence was reported as 45.3% and 2.1%, respectively, in January 2022. 69 , 71 …”

Section: Discussionmentioning

confidence: 94%

“… 77 However, BA.2 predominated from March to June 2022 while BA.4 and BA.5 started to emerge. 62 , 78 In Brazil, BA.1 predominated between December 2021 to April 2022 while BA.2 started to appear 64 , 80 ( Figure 4(a) ). Similarly, BA.1 predominated in South Africa over BA.2 and BA.5 emerged between October 2021 and April 2022) 22 , 61 ( Figure 4(b) ).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review

Sarkar,

Omar,

Alshareef

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. This review compiled data reporting the relative prevalence of Omicron as compared to the early variants to give an insight into the existing variants, which may shape the decisions regarding the targets of the newly developed vaccines. Complied data revealed more than 90% prevalence within the infected cohorts in some countries. The BA.1 subvariant predominated over the BA.2 during the early stages of the Omicron wave. Moreover, BA.4/BA.5 subvariants were detected in South Africa, USA and Italy between October 2021 and April 2022. It is therefore important to develop vaccines that protect against Omicron as well as the early variants, which are known to cause more severe complications.

show abstract

Section: Resultsmentioning

confidence: 79%